Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Longevity Biotech Awarded $225K Phase I SBIR Contract | Contract Pharma

What are you searching for?

Sign in
Breaking News

Longevity Biotech Awarded $225K Phase I SBIR Contract

For the treatment of severe asthma

By: Betsy Louda

, Contract Pharma

Longevity Biotech (LBT) has been awarded a Phase I SBIR Contract from the National Heart, Lung, and Blood Institute (NHLBI) to further the development of the 5A apoA-I mimetic peptide program for the treatment of severe asthma. 

 

The overall goal of this project is to prepare an inhalational 5A apoA-I mimetic peptide that will become the subject of a future Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) initially focused on patients who do not respond to standard corticosteroid treatment.

 

“We are honored to be selected by the NHLBI/NIH to help develop this program, which expands both our immunological portfolio as well as our capabilities in less-invasive peptide delivery,” said Dr. Scott Shandler, Ph.D., co-founder and chief executive officer of Longevity Biotech. 

 

This project has been fully funded with federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN268201700022C.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics